Stifel Reiterates Buy Rating on Boston Scientific, Targets $65
Stifel maintains its buy rating on Boston Scientific with a $65 price target, a 46.96% upside from the current price.
Key Points
- Stifel reiterated its buy rating for Boston Scientific, setting a price target of $65.
- Stifel's $65 price target implies 46.96% upside from Boston Scientific Corporation's ($BSX) current $44.23 share price.
- Boston Scientific's stock traded near $44.62 on Thursday, with a market cap of $65.9 billion.
- Analysts maintain a strong buy consensus with a target mean price of $76.48.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Stifel has reiterated its buy rating for Boston Scientific Corporation (NYSE: BSX), setting a price target of $65. This decision was announced on June 25, 2026, by analyst Rick Wise. Boston Scientific shares traded near $44.62 on Thursday.
Stifel vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Boston Scientific Corporation Stock Down 5.6%
Shares of NYSE:BSX traded around $44.62 on Thursday. Boston Scientific has a market cap of approximately $65.9 billion and a P/E ratio of 18.5. The company's forward P/E is 11.9, and it has a beta of 0.559, indicating lower volatility compared to the market. The stock's 52-week range is between $44.05 and $109.50, with moving averages of $54.92 over 50 days and $81.20 over 200 days. The company maintains a current ratio of 1.9 and a quick ratio of 0.98, with a debt-to-equity ratio of 42.25.
$BSX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Boston Scientific reported revenue of $20.6 billion, showing a growth of 11.6%. The company's net margin stands at 17.3%, with a return on equity of 14.7%. Earnings per share (EPS) are reported at $2.39. The next earnings report is expected on July 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Boston Scientific Corporation
Several insiders have been active in May 2026. CEO Michael Mahoney sold 386,755 shares on May 28. On the buying side, David Habiger purchased 2,250 shares at $55.92 on May 20 and 2,200 shares at $56.95 on May 19. Edward Ludwig acquired 3,580 shares at $56.68, Cheryl Pegus bought 1,770 shares at $56.49, and Ellen Zane bought 3,800 shares earlier in May.
Analysts Set New Price Targets
On June 25, 2026, Stifel maintained its buy rating with a $65 price target for Boston Scientific. Jefferies also maintained a buy rating with a $67 target on June 24. BTIG reiterated a buy rating with a $65 target on June 16. The consensus among analysts is a strong buy, with a target mean price of $76.48 based on 29 opinions.
About Boston Scientific Corporation
Boston Scientific Corporation, headquartered in Marlborough, Massachusetts, develops, manufactures, and markets medical devices globally. The company operates in the MedSurg and Cardiovascular segments, offering a range of devices for gastrointestinal, urological, neurological, and cardiovascular conditions. Led by CEO Michael F. Mahoney, Boston Scientific employs around 59,000 people.
Bottom Line
Stifel's reiteration of its buy rating for Boston Scientific, with a $65 target, reflects ongoing analyst confidence. Boston Scientific's stock performance and analyst consensus indicate strong market interest, although investors should remember this analysis is based on past data. The next earnings report will provide further insight into the company's financial health.
Get Boston Scientific Corporation alerts
New 13F filings, insider trades, and analyst moves on $BSX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.